NEWS & EVENTS

Latest news and upcoming events

Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension
09 Jun 2022

Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension

Upcoming events
  • ESMO Congress
    9 – 13 September 2022,
    Paris

    download
  • 22nd Annual Biotech in Europe Forum
    21 - 22 September, 2022
    Basel

    download
  • Brain Innovation Days
    11 – 12 October 2022,
    Brussels

    download
Xeltis receives commitment from Grand Pharma to invest €15M as cornerstone of ongoing Series D2 financing round<

Xeltis receives commitment from Grand Pharma to invest €15M as cornerstone of ongoing Series D2 financing round

Xeltis’ first commercial deal and its first funding from an Asian company

Study shows that selection of breast cancer patients for adjuvant bisphosphonate therapy based on Inbiomotion’s MAFTEST® reduces the risk of death in comparison with current clinical guidance<

Study shows that selection of breast cancer patients for adjuvant bisphosphonate therapy based on Inbiomotion’s MAFTEST® reduces the risk of death in comparison with current clinical guidance

Reduces the risk of death at 5 and 10 years by 26% and 23% respectively.

Declaration of conformity drawn up for MAFTEST®<

Declaration of conformity drawn up for MAFTEST®

The MAFTEST®, is intended to detect in the tumor the amplification involving the MAF gene region in order to determine the risk in early-stage breast cancer patients.

Am-Pharma announces publication of in vivo acute kidney injury study demonstrating ilofotase alfa’s dual protective mechanism<

Am-Pharma announces publication of in vivo acute kidney injury study demonstrating ilofotase alfa’s dual protective mechanism

Study shows ilofotase alfa protects against ischemia-reperfusion induced acute kidney injury in rodents

Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer<

Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Aura expects to initiate the trial in the second half of 2022, with initial Phase 1 data expected in 2023.

Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma<

Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma

In this Retrospective Matched Case Control Study, Belzupacap Sarotalocan Achieved Statistically Significant Vision Preservation

Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting<

Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting

We remain on track with our Phase 2 SC study and we plan to finalize a decision on the route of administration and initiate our pivotal program before the end of the year.

LAVA Therapeutics highlights encouraging clinical updates on lead program, LAVA-051, in chronic lymphocytic leukemia and multiple myeloma patients<

LAVA Therapeutics highlights encouraging clinical updates on lead program, LAVA-051, in chronic lymphocytic leukemia and multiple myeloma patients

James Noble and Jay Backstrom, M.D, M.P.H, bring vast global leadership experiences at public biopharmaceutical companies

Ysios Capital appoints Wen Wen Cheng as Head of Legal<

Ysios Capital appoints Wen Wen Cheng as Head of Legal

This addition will strengthen the Ysios Capital team by incorporating an expert in legal matters.

LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients<

LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients

James Noble and Jay Backstrom, M.D, M.P.H, bring vast global leadership experiences at public biopharmaceutical companies

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.